(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
Trial details
- Registry ID
- NCT05208047
- Drugs studied
- Bezuclastinib, CGT9486, Midazolam, Sunitinib
TrialRedline tracks 3 clinical trials sponsored by Cogent Biosciences, Inc.: 1 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal TumorsNCT05208047 | Bezuclastinib, CGT9486, Midazolam, Sunitinib | Recruiting | 2025-09-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisNCT04996875 | bezuclastinib | Recruiting | 2025-09-19Actual |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisNCT05186753 | Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B) | Active not recruiting | 2025-05-22Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-11-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | GIST | Open original sourceRead source excerptPreparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | NonAdvSM | Open original sourceRead source excerptWe submitted the first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026. The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-30Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | NonAdvSM | Open original sourceRead source excerptPotential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |
| 2027-06-29Day | bezuclastinibCogent Biosciences, Inc. · COGT | Company-disclosed PDUFA goal dateAnnounced review target | AdvSM | Open original sourceRead source excerptPotential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |
Names as written in the registry records.
NCT05208047 · Cogent Biosciences, Inc.
Before: Active not recruiting. After: Recruiting.
NCT05208047 · Cogent Biosciences, Inc.
Before: 442 participants (planned). After: 482 participants (planned).
NCT04996875 · Cogent Biosciences, Inc.
Before: Estimated. After: Actual.
Before: Sep 2025. After: 19 Sep 2025.
NCT05208047 · Cogent Biosciences, Inc.
Before: Estimated. After: Actual.
Before: Jul 2025. After: 30 Sep 2025.